ORIGINAL RESEARCH article

Front. Endocrinol.

Sec. Cancer Endocrinology

Volume 16 - 2025 | doi: 10.3389/fendo.2025.1536301

This article is part of the Research TopicInnovative Diagnostic and Therapeutic Strategies for Neuroendocrine Tumors: A Multidisciplinary ApproachView all articles

Impact of hyperglycaemia and antidiabetic medication on pancreatic uptake on [ 68 Ga]Ga-DOTATOC PET/CT

Provisionally accepted
Sophie  Carina KunteSophie Carina Kunte1,2*Thorsten  SiegmundThorsten Siegmund3Maximilian  TilingMaximilian Tiling1Lukas  OstermairLukas Ostermair4Lena  Maria UnterrainerLena Maria Unterrainer1,2,5Marily  TheodoropoulouMarily Theodoropoulou4Martin  ReinckeMartin Reincke4Friederike  VölterFriederike Völter1,4
  • 1Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Bavaria, Germany
  • 2Bayerisches Zentrum für Krebsforschung (BZKF), partner site Munich, Munich, Bavaria, Germany
  • 3Division for Endocrinology, Diabetology and Metabolism, Isar Clinic Munich, Munich, Germany
  • 4Department of Medicine IV, Endocrinology, Diabetes and Metabolism LMU University Hospital, LMU Munich, Munich, Germany
  • 5David Geffen School of Medicine at UCLA, Ahmanson Translational Theranostics Division, UCLA Health System, Los Angeles, California, United States

The final, formatted version of the article will be published soon.

Positron-emission-tomography-(PET)/computed-tomography-(CT) using somatostatin-receptor-(SSTR)-binding radioligands is well established in the imaging of neuroendocrine tumors (NETs). SSTRs are expressed in NETs and endocrine and exocrine tissues, e.g. pancreas, where somatostatin binding to SST2 and SST5 inhibits glucagon and insulin secretion. Pancreatic background activity on SSTR-PET varies widely and is increased in up to 45% of cases. High uptake in the processus uncinatus can obscure NETs or cause false positives. The determinants of elevated pancreatic activity on SSTR-PET remain unclear, prompting investigation into the association between pancreatic radioligand uptake and diabetic status.All patients with non-pancreatic NETs undergoing [68Ga]Ga-DOTATOC-PET/CT at LMU clinic with available HbA1c were included. Patients were grouped: without glucose metabolism disorder (HbA1c 4.0-5.6%), prediabetes (HbA1c 5.7-6.4%), type 2 diabetes mellitus. Pancreatic volume and tracer uptake were assessed, with correlation and regression analyses between SSTR expression and HbA1c. The study included 40 patients (54 scans; n=22: normal glucose metabolism, n=20: prediabetes, n=12: diabetes; n=11: antidiabetic medication (AM)). Patients with normal glucose homeostasis showed increased tracer-uptake than those with impaired glucose metabolism (p=0.033; p=0.009). Correlation analysis revealed a significant negative correlation of HbA1c and SUVmax in patients without AM (r2=0.267; p<0.001). Multiple linear regression analysis with AM as a covariate revealed a significant association between HbA1c and SUVmax (r2=0.667; CI -0.371 to -0.135; p<0.001), AM was a significant covariate (CI 1.393 to 2.120; p<0.001). The association between HbA1c and SUVmean showed a trend (p=0.061) but no statistical significance.Our findings indicate a significant association between pancreatic [68Ga]Ga-DOTATOC-uptake and glucose metabolism, suggesting that [68Ga]Ga-DOTATOC-PET/CT sensitivity for detecting pancreatic NETs may be affected by individual glucose homeostasis.

Keywords: Glucose, diabetes, Pancreas, HbA1c, SSTR PET/CT, Sst, [ 68 Ga]Ga-DOTATOC, Sensitivity

Received: 28 Nov 2024; Accepted: 23 Apr 2025.

Copyright: © 2025 Kunte, Siegmund, Tiling, Ostermair, Unterrainer, Theodoropoulou, Reincke and Völter. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Sophie Carina Kunte, Department of Nuclear Medicine, LMU University Hospital, LMU Munich, Munich, Bavaria, Germany

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.